|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
DeFriend DJ et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54(2):408-14. Abstract
Delozier T et al. Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann Oncol 2000;11(5):515-9. Abstract
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract
Kuter I et al. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2007;Abstract 23.
Mackey JR et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 3.
Robert NJ et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Proc ASCO 2006;Abstract 550.
Robertson JF et al. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer 2007a;43(1):64-70. Abstract
Robertson JF et al. Fulvestrant in the treatment of HER2-positive advanced breast cancer (ABC). Proc ASCO 2007b;Abstract 1061.
Robertson JF et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61(18):6739-46. Abstract
Steger G et al. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer — A pilot study. Proc ASCO 2005;Abstract 708.
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
Young OE et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 2008;44(3):391-9. Abstract
 |
 |
EDITOR'S NOTE
Bev, BETH, BEATRICE and the next big moment in oncology
research: NSABP-C-08
Neil Love, MD
- Select publication
INTERVIEWS
Daniel F Hayes, MD
- Select publications
John F Forbes, MD
- Select publications
Julie R Gralow, MD
- Select publications
John F R Robertson,
MB, ChB, BSc, MD
- Select publications
Roundtable Discussion
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
